Ray Co., Ltd. (KOSDAQ:228670)
South Korea
· Delayed Price · Currency is KRW 8,120.00
+550.00 (7.27%)
Apr 1, 2025, 3:30 PM KST
Ray Co., Ltd. Revenue
In the year 2024, Ray Co., Ltd. had annual revenue of 79.84B KRW, down -45.27%. Ray Co., Ltd. had revenue of 15.26B in the quarter ending December 31, 2024, a decrease of -68.18%.
Revenue
79.84B
Revenue Growth
-45.27%
P/S Ratio
1.59
Revenue / Employee
385.71M
Employees
207
Market Cap
125.97B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 79.84B | -66.04B | -45.27% |
| Dec 31, 2023 | 145.88B | 16.88B | 13.09% |
| Dec 31, 2022 | 129.00B | 38.66B | 42.80% |
| Dec 31, 2021 | 90.34B | 35.13B | 63.64% |
| Dec 31, 2020 | 55.20B | -17.90B | -24.49% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,547.32B |
| Celltrion | 3,557.30B |
| ALTEOGEN | 102.85B |
| Yuhan | 2,067.79B |
| SK Biopharmaceuticals | 547.60B |
| HLB Co., Ltd. | 51.92B |
| Sam Chun Dang Pharm. | 210.92B |
| PharmaResearch | 350.12B |